TrialCard Incorporated, a company involved in access, affordability, adherence, and engagement solutions for patients and healthcare providers, announced yesterday that it has named Karen L Russell as its new chief financial officer, effective immediately.
Russell will assume the role from Interim CFO, Mark Bogovich.
Russell brings to TrialCard more than 20 years of experience in global finance and she has an extensive background in leadership, strategic planning, business operations, change management, and system deployment. She most recently served as CFO for Evidera. Prior to that, she enjoyed a long career in finance at GSK, where her last role was VP, Finance for the Respiratory Business Unit, US Pharma.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA